CXorf48 is a potential therapeutic target for achieving treatment-free remission in CML patients.
Matsushita M, Ozawa K, Suzuki T, Nakamura M, Nakano N, Kanchi S, Ichikawa D, Matsuki E, Sakurai M, Karigane D, Kasahara H, Tsukamoto N, Shimizu T, Mori T, Nakajima H, Okamoto S, Kawakami Y, Hattori Y.
Matsushita M, et al. Among authors: matsuki e.
Blood Cancer J. 2017 Sep 1;7(9):e601. doi: 10.1038/bcj.2017.84.
Blood Cancer J. 2017.
PMID: 28862699
Free PMC article.